Massachusetts Institute of Technology (MIT) - David H. Koch Institute for Integrative Cancer Research; Massachusetts Institute of Technology (MIT) - Department of Biology; Harvard Medical School
Massachusetts Institute of Technology (MIT) - David H. Koch Institute for Integrative Cancer Research; Massachusetts Institute of Technology (MIT) - Department of Biology
Massachusetts Institute of Technology (MIT) - David H. Koch Institute for Integrative Cancer Research; Brigham and Women’s Hospital - Department of Pathology
Massachusetts Institute of Technology (MIT) - David H. Koch Institute for Integrative Cancer Research; Massachusetts Institute of Technology (MIT) - Department of Biology; Massachusetts Institute of Technology and Harvard University - Broad Institute; Massachusetts Institute of Technology (MIT) - Howard Hughes Medical Institute (HHMI)
Massachusetts Institute of Technology (MIT) - David H. Koch Institute for Integrative Cancer Research; Massachusetts Institute of Technology (MIT) - Department of Biology; Massachusetts Institute of Technology (MIT) - Howard Hughes Medical Institute (HHMI)
Regulatory T cells (Tregs) can impair anti-tumor immune responses and are associated with poor prognosis in multiple cancer types. Tregs in human tumors span diverse transcriptional states distinct from those of peripheral Tregs, but their contribution to tumor development remains unknown. Here, we used single cell RNA-Seq to longitudinally profile conventional CD4+ T cells (Tconv) and Tregs in a genetic mouse model of lung adenocarcinoma. Tissue-infiltrating and peripheral CD4+ T cells differed, highlighting divergent pathways of activation during tumorigenesis. Longitudinal shifts in Tregs heterogeneity suggested stabilization of a specialized effector phenotype over time that had enhanced expression of the interleukin 33 receptor ST2. Tregs-specific deletion of ST2 altered lung effector Tregs diversity, increased infiltration of CD8+ T cells into tumors, and decreased tumor burden. Our study shows that ST2 plays a critical role in Tregs-mediated immunosuppression in cancer, highlighting new potential paths for therapeutic intervention.
Li, Amy and Herbst, Rebecca H. and Canner, David and Schenkel, Jason M. and Smith, Olivia C. and Kim, Jonathan Y. and Hillman, Michelle and Bhutkar, Arjun and Cuoco, Michael S. and Rappazzo, C. Garrett and Rogers, Patricia and Dang, Celeste and Jerby-Arnon, Livnat and Rozenblatt-Rosen, Orit and Cong, Le and Birnbaum, Michael and Regev, Aviv and Jacks, Tyler E., Longitudinal Single Cell Profiling of Regulatory T Cells Identifies IL-33 as a Driver of Tumor Immunosuppression (March 15, 2019). Available at SSRN: https://ssrn.com/abstract=3353223 or http://dx.doi.org/10.2139/ssrn.3353223
This version of the paper has not been formally peer reviewed.